Quarterly ResultMay 12, 2026, 07:02 AM
CalciMedica Reports Q1 Net Income $5M; Auxora AP Program Advances
AI Summary
CalciMedica reported a net income of $5.0 million, or $0.30 diluted EPS, for Q1 2026, a significant improvement from a $5.0 million net loss in Q1 2025, primarily due to a $9.1 million increase in other income from fair value adjustments. The company continues to engage with the FDA regarding the pivotal program design for Auxora in acute pancreatitis (AP), with feedback expected in Q2 2026, following positive Phase 2b CARPO trial results published in eClinicalMedicine. Additionally, FDA feedback on Auxora's potential future development in acute kidney injury (AKI) is also anticipated in Q2 2026, and preclinical studies for CM5480 in pulmonary hypertension are advancing towards a 2027 IND submission.
Key Highlights
- Q1 2026 net income was $5.0 million, up from a $5.0 million net loss in Q1 2025.
- Diluted EPS for Q1 2026 was $0.30, compared to $(0.36) in Q1 2025.
- Other income increased by $9.1 million to $10.6 million, driven by fair value adjustments.
- R&D expenses decreased by $0.7 million to $3.5 million in Q1 2026.
- Cash and cash equivalents were $8.2 million as of March 31, 2026, funding operations into Q4 2026.
- FDA feedback on Auxora's pivotal program in acute pancreatitis expected in Q2 2026.
- Phase 2b CARPO trial results for Auxora in AP published, showing dose-dependent improvements.
- IND submission for oral CRAC channel inhibitor CM5480 in pulmonary hypertension anticipated in 2027.